Older patients are eligible for trial of lithium and valproate

BMJ 2003; 327 doi: 10.1136/bmj.327.7411.395-b (Published 14 August 2003)
Cite this as: BMJ 2003;327:395.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Jennifer M Rendell (jennifer.rendell@psych.ox.ac.uk), BALANCE trial manager,
  2. John R Geddes, professor of epidemiological psychiatry,
  3. Michael J Ostacher, instructor in psychiatry
  1. Department of Psychiatry, Warneford Hospital, Oxford OX3 7JX
  2. Harvard Bipolar Research Program, Massachussetts General Hospital, 50 Staniford Street, Suite 580, Boston, MA 02114, USA on behalf of the BALANCE Investigators

    EDITOR—Shulman et al report an increase in the prescription of valproate for elderly patients with bipolar disorder in Canada (and corresponding decrease in prescription of lithium).1 A similar pattern has been observed in the United States over the past decade or so.2 As the authors note, this change has occurred despite the …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL